Keytruda, Ibrance On Course To India Debut But What About Pricing?
This article was originally published in Scrip
Executive Summary
Merck & Co's Keytruda (pembrolizumab), the first PD-1 inhibitor approved by the FDA last year, and Pfizer's breast cancer therapy, Ibrance (palbociclib), appear to be on course to a potential Indian debut after a key local expert panel recommended the products for marketing.